Carl Zeiss Meditec (OTCMKTS:CZMWY) Downgraded by Zacks Research to “Strong Sell”

Carl Zeiss Meditec (OTCMKTS:CZMWY) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Tuesday,Zacks.com reports.

Separately, UBS Group downgraded Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Carl Zeiss Meditec has a consensus rating of “Reduce”.

Carl Zeiss Meditec Price Performance

Carl Zeiss Meditec stock opened at $34.41 on Tuesday. Carl Zeiss Meditec has a 52 week low of $26.65 and a 52 week high of $55.94. The company’s 50 day moving average price is $32.16 and its two-hundred day moving average price is $31.08.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG is a global medical technology company headquartered in Jena, Germany. Founded in 2002 as a spin-off from the Carl Zeiss Group, the business leverages the parent company’s expertise in optics and precision engineering. Over the years, Carl Zeiss Meditec has grown through organic development and strategic acquisitions, becoming a recognized provider of innovative surgical and diagnostic solutions for eye care and microsurgery.

The company’s core offerings span two primary divisions: Ophthalmic Devices and Microsurgery.